Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
Nautilus Biotechnology, Inc. (NAUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q2268xkearnings.htm EX-99.1 Document Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2026 Financial Results SEATTLE, WA, July 28, 2026 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,
How this was made
The 30-second read
Why it matters
Key new items are first revenue recognition in Q2 (including Michael J. Fox Foundation grant revenue and early access program service revenue), a resource reallocation toward proteoform applications, and updated commercialization timelines (Voyager pre-orders early 2027, instrument shipment mid 2027; AKT1 early access late 2026; broadscale kit timeline pushed out).
Market read
Traders can reassess commercialization probability and cash runway expectations using the new Q2 financials and the updated, more proteoform-focused roadmap milestones.
What to watch
Cash is $129.2M as of June 30, 2026, but the filing does not quantify runway impact from the reallocation; traders may need to model burn rate changes and the probability of hitting late-2026 early access milestones.
Background
This SEC 8-K includes Exhibit 99.1 with Nautilus’ Q2 2026 results and an updated roadmap for its Voyager platform and proteoform assay portfolio.
Ticker impact
Nautilus reported Q2 2026 revenue of $0.2M, net loss of $14.5M, and a roadmap shift toward proteoform applications plus Voyager launch timing.
Moderate volatility possible around pre-market as traders reprice the updated Voyager and proteoform assay timelines versus prior broadscale expectations.
This is a primary SEC filing with new Q2 results (revenue, loss, cash) and specific forward-looking milestones (Voyager early 2027 pre-orders, instrument mid 2027; AKT1 early access late 2026; broadscale kit timeline deferred). However, the company is still pre-commercial and the release does not include guidance ranges or consensus beats/misses.
Market effects
Adds datapoints for early-stage proteomics platform companies on commercialization timing and the importance of assay consumables readiness.
Limited, primarily affects US small-cap biotech/proteomics sentiment.
Low; no direct cross-border deal or regulatory action disclosed.
Counterpoint
The roadmap shift may signal technical or commercial underperformance in broadscale assays, and the company still reports only $0.2M revenue with a $14.5M quarterly net loss.
Key entities
- companyNautilus Biotechnology, Inc.
Reports Q2 2026 financial results and updates its proteoform and Voyager commercialization roadmap.
- organizationMichael J. Fox Foundation
Grant revenue source supporting alpha-synuclein proteoform assay development mentioned in Q2 revenue drivers.
- productVoyager™ Platform
Instrument platform with launch expected early 2027 for pre-orders and mid 2027 for instrument shipment.
- productAKT1 Proteoforms Assay
Oncology proteoform assay selected for advancement, with early access expected late 2026.
- productBroadscale Assay
Assay configuration changes did not meet target specifications for a 2027 general availability consumable kit; timeline deferred.
